Established in 2002, Bioven is a wholly-owned Malaysian biotechnology and healthcare company with primary focus in the area of Oncology and Therapeutic Cancer Vaccines.
Bioven is an advanced biotechnology company that harnesses the resources of life sciences to identify, develop and commercialize effective cancer therapeutics. Fusing cutting edge technologies and strategic market-based solutions, Bioven is set to launch itself into the lucrative global pharmaceuticals market by introducing ‘first-of-a-kind’ life-saving health care products.
At Bioven, we target to turn cancer into a chronic disease area defined by world experts as the next medical barrier.
We believe ourselves to be one of only two or three biotechnology companies in the world with a phase III Lung Cancer Vaccine, the only company with a vaccine targeting the EGF pathway in clinical trials.
Bioven’s partnership with Cuba, globally acknowledged by world experts for its advanced science, enhances the credibility behind the science of the vaccines.
We believe that the long-term stabilisation of the disease seen in most patients indicate that treatment with a non-toxic immunotherapy such as the EGF Lung Cancer vaccine can transform advanced cancer into a chronic disease, bringing hope to cancer sufferers by giving them good quality of life and extended years with their loved ones.